Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) has raised 150 million yuan ($22 million) in a Series B round led by Livzon Pharmaceutical, a wholly-owned investment platform Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. In a separate development, China’s premium big data solution company Chengdu Shuzhilian Technology Company has also secured a similar amount from GF Venture Capital and existing investor Yinxinggu Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
